1.
Ross DM, Babon JJ, Tvorogov D, Thomas D. Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications. haematol [Internet]. 2021Jan.21 [cited 2022Nov.28];106(5):1244-53. Available from: https://haematologica.org/article/view/haematol.2020.262691